An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Protocol No
GENMAB-GCT3014-01
Phase
I/II
Summary

This project is being done to find out if GEN3104 (HexaBody®-CD38) is safe in patients with multiple myeloma or acute myeloid leukemia or other types of blood cancers.

Description
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Multiple Myeloma, Early Phase/Multiple Disease Site Cancers, Hematologic/Blood Related Cancers
ClinicalTrials.gov
go to website